Solokap® (Herbaceutical formula)‎ protect against fluvastatin-induced hepatitis by ameliorating oxidative stress and inflammation in female albino rats

Abstract EN

High doses of Fluvastatin (F) insure liver cells toxicity in hepatocytes function and homeostasis.

This study investigated the possible therapeutic effect of solokap (S) on hepatitis induced by F in female rats.

Animals were divided into four groups: group1 (negative control), group2 (F-control), group3, received solokap (S) only and group 4(F+S).

Rats were received F for first 10 days.

Results obtained showed that F increased alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (AlP), gamma glutamyl transpeptidase (γ-GTP), total bilirubin, malondialdhyde (MDA), tumor necrosis factor α protein (TNFα), tumor growth factorβ1 (TGFβ1), nuclear factor Kappa B (NFKB), cyclooxygenase-1 and 2 (COX-1 and 2), while, decreased the levels of albumin and total protein, reduced glutathione (GSH), Glutathione peroxidase (GPx), catalase (CAT) and interleukin-10 protein (IL-10).

Liver histological and immune-histochemical investigations of rats administered F showed sever congestion in portal vein associated with fibrosis and inflammatory cells infiltration.

Also, collagen-I stained cells were found in the portal area and the central vein.

On the other hand, animals treated with solokap showed improvements for these parameters as well as in the histological and immune-histochemical feature of the liver.

Therefore, the present results revealed that Solokap could minimize the toxic effects of Fluvastatin.